Press release
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE)
About this update from Ocugen, Inc.
[{"type":"text","content":"Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host an in-person Research & Development (R&D) Day on Tuesday, November 1, 2022. The event will take place from 9 a.m.-noon ET at the Nasdaq Market Site in Times Square, New York City. R&D Day will provide an opportunity to learn more about Ocugen’s innovations focused on improving public health and addressing unmet medical need. A scientific poster session will include a detailed look at Ocugen’s comprehensive pipeline. Two panel discussions will offer expert opinion on the current and future treatment landscape of vaccines and gene therapy. Panelists include: Neena B. Haider, PhD, Associate Professor, Schepens Eye Research Institute, Mass Eye and Ear, Department of Ophthalmology, Harvard Medical SchoolMark Pennesi, MD, PhD, Professor of Ophthalmology, Oregon Health and Science University, and a member of Ocugen’s Retina Scientific Advisory Board David Fajgenbaum, MD, MBA, MSc, Assistant Professor of Medicine, Translational Medicine & Human Genetics, University of Pennsylvania, and a member of Ocugen’s Vaccine Scientific Advisory BoardEric Feigl-Ding, ScD, Chief of COVID Task Force, Co-founder of World Health Network, Faculty of Public Health- NECSI Ocugen’s leadership will provide a business update, along with insight to how its programs in vaccines and gene and cell therapies contribute to its long-term corporate strategy. Nasdaq requires advance registration from attendees and registration can be done here or by contacting Jon Nugent, [email protected] at Tiberend Strategic Advisors, Inc. A replay will be available within 48 hours following the conclusion of the event via webcast on the events page of the Ocugen investor site. About Ocugen, Inc.Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our ...